Should new drugs be used without outcome data? Implications of ALLHAT and ELITE II

Norman M Kaplan

doi:10.1001/archinte.161.4.511

Should new drugs be used without outcome data? Implications of ALLHAT and ELITE II

Norman M Kaplan

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	511-512
Number of pages	2
Journal	Archives of Internal Medicine
Volume	161
Issue number	4
DOIs	https://doi.org/10.1001/archinte.161.4.511
State	Published - Feb 26 2001

ASJC Scopus subject areas

Internal Medicine

Access to Document

10.1001/archinte.161.4.511

Cite this

@article{9cc5f617bc604f51baad0b67866a9500,

title = "Should new drugs be used without outcome data? Implications of ALLHAT and ELITE II",

author = "Kaplan, {Norman M}",

year = "2001",

month = feb,

day = "26",

doi = "10.1001/archinte.161.4.511",

language = "English (US)",

volume = "161",

pages = "511--512",

journal = "Archives of Internal Medicine",

issn = "0003-9926",

publisher = "American Medical Association",

number = "4",

}

TY - JOUR

T1 - Should new drugs be used without outcome data? Implications of ALLHAT and ELITE II

AU - Kaplan, Norman M

PY - 2001/2/26

Y1 - 2001/2/26

UR - http://www.scopus.com/inward/record.url?scp=0035952262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035952262&partnerID=8YFLogxK

U2 - 10.1001/archinte.161.4.511

DO - 10.1001/archinte.161.4.511

M3 - Comment/debate

C2 - 11252109

AN - SCOPUS:0035952262

SN - 0003-9926

VL - 161

SP - 511

EP - 512

JO - Archives of Internal Medicine

JF - Archives of Internal Medicine

IS - 4

ER -

Should new drugs be used without outcome data? Implications of ALLHAT and ELITE II

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this